We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




X-ray Crystallography Used to Explore Placental Malaria's Chondroitin Sulfate-Binding Domain

By LabMedica International staff writers
Posted on 18 Aug 2008
Advanced X-ray crystallography techniques have been used to explore the structure of the malaria parasite's chondroitin sulfate-binding DBL3X domain from a var2csa gene-encoded PfEMP1 protein.

Malaria is the most deadly parasitic disease affecting humanity, causing 500 million serious cases and two million deaths each year. More...
People living in endemic countries develop partial immunity after multiple disease episodes, and this immunity correlates with acquisition of strain-specific antibodies that recognize PfEMP1 proteins. These proteins are expressed on the surface of infected red blood cells, where they bind to human receptors, sequestering the cells away from spleen-mediated destruction. This protects the parasite and prolongs the infection. These interactions also cause infected cells to accumulate in the brain and on the placenta during cerebral malaria and malaria of pregnancy, leading to some of the most deadly symptoms of the disease.

In malaria of pregnancy, domains from the var2csa-encoded PfEMP1 protein interact with chondroitin sulfate on the placenta surface. This causes accumulation of infected red blood cells, leading to placental inflammation and block of blood flow to the developing fetus. This is associated with maternal anemia, low birth weight, and premature delivery and can lead to the death of mother and child.

In the current study Dr. Matthew Higgins, professor of biochemistry at the University of Cambridge (UK) determined the structure of the DBL3X domain from a xenon derivative using single-wavelength dispersion data collected employing chromium K-alpha radiation that was refined to 0.18 nm resolution.

Results published in the August 8, 2008, issue of the Journal of Biological Chemistry (JBC) revealed that the domain adopted a fold similar to malarial invasion proteins, with extensive loop insertions. One loop was flexible in the unliganded structure but observed in the presence of sulfate or disaccharide, where it completed a sulfate-binding site. This loop, and others surrounding this putative carbohydrate-binding site, was flexible and polymorphic, perhaps protecting the binding site from immune detection.

This structure suggests a model for how the domain maintains ligand binding while evading the immune response and serves as a guide for future drug and vaccine development.

Related Links:
University of Cambridge



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.